TVM Settlement Agreement: Motley Rice Enters Agreement with AMS and Endo
Plaintiffs’ law firm Motley Rice LLC has reached an Agreement in Principle to settle with transvaginal mesh (TVM) device manufacturer American Medical Systems, Inc. (AMS) and parent company Endo International plc on behalf of Motley Rice and affiliated firms’ eligible TVM clients in the multidistrict litigation In re American Medical Systems, Inc., Pelvic Repair Systems Products Liability Litigation (MDL 2325).
The settlement will be implemented over the next 12 months as agreed to by the parties. This settlement will be available to approximately 6,000 women who used AMS’s transvaginal mesh device.
“Endo International and American Medical Systems treated these negotiations professionally in addressing our clients’ claims,” stated Motley Rice co-founding member attorney Joe Rice (DC, SC). “This Settlement has been the result of adversarial but respectful and professional negotiation on the part of all of the parties. I commend the work of all involved, including Henry Garrard, one of the Coordinating Co-Lead Counsel in the MDL, as well as the Endo and AMS teams. It has been refreshing to work with a corporation and its counsel at Arnold & Porter LLP in a manner that allows for true negotiation while maintaining respect for the needs of our clients.”
“The settlement discussions began under the watchful eye of the federal court in West Virginia. We are grateful for the MDL court’s assistance in facilitating the negotiating process and look forward to continuing to work with the Honorable Judge Joseph R. Goodwin, who has been assigned the task of managing this massive multidistrict litigation,” added Rice.
Motley Rice’s Settlement Agreement does not impact all TVM cases. Additional cases remain with other law firms. Litigation with other TVM manufacturers, including Boston Scientific, C.R. Bard, Inc., and Johnson & Johnson, remains as they have yet to negotiate settlement agreements.
From 2005 to 2010, nearly 4,000 injuries were reported to the FDA following the placement of TVM devices.
View the Court Approved Settlement Framework and Methodology: